Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase implicated in human cancer development.
• ALK fusions, such as NPM-ALK, are confirmed oncogenic drivers in anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMTs).
• Full-length ALK receptor signaling, potentially activated by ligands pleiotrophin (PTN) and midkine (MK), is also linked to cancers like glioblastoma and neuroblastoma.

Purpose of the Study:

• To review the normal biology of ALK.
• To summarize the established and potential roles of ALK fusions and full-length ALK in human cancer genesis.
• To outline current efforts in developing small-molecule kinase inhibitors targeting ALK.

Main Methods:

• Literature review of studies on ALK biology, ALK-driven malignancies, and ALK inhibitor development.
• Analysis of established and proposed mechanisms of ALK involvement in tumorigenesis.
• Summary of preclinical and clinical research on ALK-targeted therapies.

Main Results:

• ALK fusions are definitively linked to ALCL, IMTs, and potentially esophageal squamous cell carcinomas.
• Circumstantial evidence suggests the involvement of full-length ALK in glioblastoma, neuroblastoma, breast cancer, and other malignancies.
• No ALK small-molecule inhibitors are currently approved for clinical cancer therapy, but developmental efforts are active.

Conclusions:

• ALK is a significant factor in the pathogenesis of diverse human cancers.
• Targeting ALK, through its fusion forms or full-length receptor, represents a promising therapeutic strategy.
• Further research and development of ALK inhibitors are crucial for advancing cancer treatment.